4.7 Article

Antithrombotic Drug Use, Cerebral Microbleeds, and Intracerebral Hemorrhage A Systematic Review of Published and Unpublished Studies

期刊

STROKE
卷 41, 期 6, 页码 1222-1228

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.109.572594

关键词

antiplatelet agents; intracerebral hemorrhage; microbleeds; stroke; warfarin

资金

  1. UK Medical Research Council
  2. Dunhill Medical Trust
  3. Stroke Association
  4. BUPA Foundation
  5. National Institute for Health Research (NIHR)
  6. Thames Valley Primary Care Research Partnership
  7. NIHR Oxford Biomedical Research Centre
  8. Wellcome Trust
  9. Binks Trust
  10. Ministry for Health, Welfare & Family Affairs, Republic of Korea [A080503]
  11. MRC [G108/613] Funding Source: UKRI
  12. Medical Research Council [O12345678, G108/613, G0700704B] Funding Source: researchfish

向作者/读者索取更多资源

Background and Purpose-Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs. Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA). Methods-We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB. Results-In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference = 0.01). There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P < 0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P = 0.33; P difference = 0.01). There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3-2.3; P < 0.001), but findings were similar for antiplatelet users with IS/TIA (OR, 1.4; 95% CI, 1.2-1.7; P < 0.001; P difference = 0.25). In pooled follow-up data for 768 antithrombotic users, presence of MB at baseline was associated with a substantially increased risk of subsequent ICH (OR, 12.1; 95% CI, 3.4-42.5; P < 0.001). Conclusions-The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH. Limited prospective data corroborate these findings, but larger prospective studies are urgently required. (Stroke. 2010; 41: 1222-1228.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据